Biopharmaceutical company.
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.  

2016 CMS proposed rule implementing a new Part B drug payment model.  

H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models. H.R. 34: 21st Century Cures Act conference report.

Education about the value of innovative new medicines.
MMM - Medicare/Medicaid HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 2 - HOUSE OF REPRESENTATIVES
W STRATEGIES, LLC
1455 Pennsylvania Avenue, NW, Suite 400, Washington, DC, 20004, US
DARREN WILLCOX DARREN WILLCOX